| Symbol | VERA |
|---|---|
| Name | VERA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 8000 MARINA BOULEVARD,SUITE 120, BRISBANE, California, 94005, United States |
| Telephone | +1 650 770-0077 |
| Fax | — |
| — | |
| Website | https://www.veratx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001831828 |
| Description | Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The companys lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Vera Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001907884-26-000015 <b>Size:</b> 9 KB
Read moreNew Form 4/A - Vera Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001859453-26-000013 <b>Size:</b> 15 KB
Read moreNew Form 4/A - Vera Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001859453-26-000012 <b>Size:</b> 11 KB
Read moreNew Form 4/A - Vera Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001859453-26-000011 <b>Size:</b> 11 KB
Read more(10% Negative) VERA THERAPEUTICS, INC. (VERA) Reports Q3 2026 Financial Results
Read moreVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
Read moreVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form SCHEDULE 13G - Vera Therapeutics, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000554 <b>Size:</b> 8 KB
Read moreVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06983028 | Atacicept in Multiple Glomerular Diseases | Phase2 | pMN | Recruiting | 2025-07-07 | 2027-11-01 | ClinicalTrials.gov |
| NCT07020923 | Monthly Dosing of Atacicept in IgAN | Phase2 | IgA Nephropathy (IgAN) | Active_Not_Recruiting | 2025-05-29 | 2027-09-01 | ClinicalTrials.gov |
| NCT06674577 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | Phase2 | IgA Nephropathy (IgAN) | Enrolling_By_Invitation | 2024-12-01 | 2031-05-21 | ClinicalTrials.gov |
| NCT04716231 | Atacicept in Subjects With IgA Nephropathy | Phase3 | IgA Nephropathy | Active_Not_Recruiting | 2023-06-29 | 2028-07-01 | ClinicalTrials.gov |
| NCT05609812 | Atacicept in Subjects With Active Lupus Nephritis (COMPASS) | Phase3 | Lupus Nephritis (LN) | Withdrawn | 2022-11-02 | 2028-12-15 | ClinicalTrials.gov |
| NCT04294472 | A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK… | Phase2 | BK Virus Infection | Completed | 2020-08-05 | 2022-02-10 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Atacicept | Other | Phase PHASE2 | pMN | RECRUITING | NCT06983028 |
| Atacicept 150 mg | Other | Phase PHASE2 | IgA Nephropathy (IgAN) | ENROLLING_BY_INVITATION | NCT06674577 |
| Placebo | Other | Phase PHASE2 | BK Virus Infection | COMPLETED | NCT04294472 |
| MAU868 | Other | Phase PHASE2 | BK Virus Infection | COMPLETED | NCT04294472 |
| Atacicept 150 mg | Other | Phase PHASE2 | IgA Nephropathy (IgAN) | ENROLLING_BY_INVITATION | NCT06674577 |
| Placebo | Other | Phase PHASE3 | Lupus Nephritis (LN) | WITHDRAWN | NCT05609812 |
| Atacicept | Other | Phase PHASE3 | Lupus Nephritis (LN) | WITHDRAWN | NCT05609812 |
| Placebo to match Atacicept | Other | Phase PHASE3 | IgA Nephropathy | ACTIVE_NOT_RECRUITING | NCT04716231 |
| Atacicept | Other | Phase PHASE3 | IgA Nephropathy | ACTIVE_NOT_RECRUITING | NCT04716231 |
| Atacicept | Other | Phase PHASE2 | pMN | RECRUITING | NCT06983028 |
| Atacicept | Other | Phase PHASE2 | IgA Nephropathy (IgAN) | ACTIVE_NOT_RECRUITING | NCT07020923 |
| Atacicept 150 mg | DRUG | Phase PHASE2 | IgA Nephropathy (IgAN) | ENROLLING_BY_INVITATION | NCT06674577 |
| Placebo to match Atacicept | OTHER | Phase PHASE3 | IgA Nephropathy | ACTIVE_NOT_RECRUITING | NCT04716231 |
| Atacicept | DRUG | Phase PHASE2 | IgA Nephropathy (IgAN) | RECRUITING | NCT07020923 |
| Placebo | DRUG | Phase PHASE3 | Lupus Nephritis (LN) | WITHDRAWN | NCT05609812 |
| MAU868 | DRUG | Phase PHASE2 | BK Virus Infection | COMPLETED | NCT04294472 |